Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Remicade cost?

See the DrugPatentWatch profile for Remicade

How much does Remicade (infliximab) cost?

Prices for Remicade vary widely based on the dose (mg), infusion schedule, where you live, and whether you have insurance. Remicade is a prescription drug given by intravenous infusion, and its cost is typically discussed as part of infusion care rather than a single retail “sticker price.”

What drives the total cost of Remicade—drug price vs infusion fees?

Even when the medication cost is known, the total you pay can also depend on:
- Infusion administration charges (clinic/hospital time and supplies)
- Lab monitoring tied to biologic therapy
- Whether you’re treated under pharmacy benefits vs medical benefits
- Your infusion setting (hospital outpatient vs infusion center vs other provider sites)

Does insurance usually cover Remicade?

Many people with commercial insurance get Remicade covered, but coverage can differ by:
- Prior authorization requirements
- Coverage rules (often tied to specific diagnoses or treatment history)
- Copay/coinsurance amounts after your deductible
- Whether Remicade is on your plan’s preferred biologic list

What if you don’t have insurance—are there discounts or patient assistance?

Uninsured and underinsured patients often have options such as manufacturer programs or patient assistance programs, but availability and eligibility depend on the specific program rules in your country and your income/insurance status.

Are there cheaper alternatives?

If cost is the main issue, patients and clinicians often look at:
- Biosimilars to infliximab (same active ingredient class, typically lower list prices)
- Switching to a different biologic depending on the condition being treated
Whether switching is appropriate depends on your diagnosis, prior response, and safety history.

How to get an accurate Remicade cost for your situation

To get a real number, the most reliable path is asking your infusion provider for:
- The billed amount for the Remicade dose you need
- The infusion administration fee
- Your estimated out-of-pocket cost based on your specific insurance plan (copay/coinsurance and deductible status)

If you tell me your country, whether you’re insured, and what condition you’re treating (e.g., Crohn’s, ulcerative colitis, rheumatoid arthritis), I can suggest the most likely pricing path to ask your provider about.



Other Questions About Remicade :

remicade cost per vial How often are remicade infusions scheduled for crohn's? Remicade wac price? Cost of remicade? Evaluate the biologic company remicade on patents? How much does remicade cost? Can remicade cause a serious infusion reaction?

AI-Drug Label Prescribing Information Alignment Report

95
95%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI response correctly identifies that REMICADE label sections 5.1 (Serious Infections) and 5.2 (Malignancies) support the claim, with no contradictions and no apparent missing material information relative to the narrow claim.


Category Scores

Warnings
98
Excellent

Accurate Statements

Patients treated with REMICADE are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.
Supported by Warnings and Precautions 5.1 (Serious Infections)
Treatment with REMICADE should not be initiated in patients with an active infection (including clinically important localized infections).
Supported by Warnings and Precautions 5.1 (Serious Infections)
REMICADE should be discontinued if a patient develops a serious infection or sepsis.
Supported by Warnings and Precautions 5.1 (Serious Infections)
Patients should be closely monitored for signs and symptoms of infection during and after treatment, including tuberculosis.
Supported by Warnings and Precautions 5.1 (Serious Infections) and Monitoring language within that section
Malignancies, some fatal, have been reported among children, adolescents and young adults who received treatment with TNF blockers including REMICADE.
Supported by Warnings and Precautions 5.2 (Malignancies)
Lymphomas (including Hodgkin's and non-Hodgkin's) have been reported; postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported with fatal outcomes.
Supported by Warnings and Precautions 5.2 (Malignancies), including Lymphomas and HSTCL subsections
Melanoma and Merkel cell carcinoma have been reported with TNF blocker therapy including REMICADE.
Supported by Warnings and Precautions 5.2 (Malignancies), Skin Cancer subsection
In controlled trials, more REMICADE-treated patients developed malignancies than placebo-treated patients.
Supported by Adverse Reactions 6.1 (Clinical Trials Experience) malignancy statement

Unsupported Statements


Contradictions


Important Omissions

The assessment does not explicitly mention that there is a boxed warning content related to malignancy risk in the label (though it is not clearly a factual claim in the AI response content beyond noting coverage of malignancy risk).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The response stays within the narrow label-supported themes (serious infections and malignancy) and does not introduce dosing, contraindications, or management instructions beyond what is supported by the label excerpts cited.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Minor omission/under-specification: explicit boxed-warning identification was not included in the evaluated claim-citations.

Suggested Improvement
Explicitly cite the boxed-warning/prescribing-information boxed section (if required by the audit standard) alongside 5.2 when discussing malignancy risk, while keeping the rest of the assessment unchanged.